Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an announcement.
Shanghai Fosun Pharmaceutical announced the acceptance of drug registration applications for two of its subsidiary companies’ products by the National Medical Products Administration. This development marks a significant step for the company in expanding its pharmaceutical offerings, particularly with drugs targeting gram-negative bacterial infections and severe hypertension, potentially enhancing its market position.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of medical drugs. It is involved in the research and commercialization of various pharmaceutical products, primarily catering to the health needs of the Chinese market.
YTD Price Performance: 1.98%
Average Trading Volume: 5,180
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.13B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.
